Alvotech
HealthcareNASDAQ:ALVO · NASDAQ Global Market
-$0.05 today
Vol 0.53M · Avg 0.57M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-9.8%
avg 41.6%
ROIC
1.3%
avg -18.7%
ROA
1.9%
avg -27.1%
Analysis
ROA is currently the strongest return metric at 1.9% versus its period average of -27.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Vilhelm Robert Wessman | Founder & Executive Chairman | $2.89M | — | 57 | — | — |
Lisa Graver | Chief Executive Officer | $186,000.00 | — | 54 | — | — |
Benedikt Stefansson | Vice President of Investor Relations and Global Communications | — | — | — | — | — |
Harshika Sarbajna | Senior Vice President of Commercial - North America | — | — | — | — | — |
Agne Pasko | Vice President & Head of Business Development | — | — | — | — | — |
Kathryn Gunnarsson | Senior Vice President of Global Talent & People Experience | — | — | — | — | — |
Linda Jonsdottir | Chief Financial Officer | — | — | 48 | — | — |
Sarah Macleod | Head of Global Communications | — | — | — | — | — |
Anthony Maffia | Chief Quality & Regulatory Officer | — | — | — | — | — |
Neha Patel | Chief Information Officer | — | — | — | — | — |
Tanya Zharov | General Counsel | — | — | 59 | — | — |
Trisha Durant | Senior Vice President of Global Business Development and Commercial Operation, ex-North America | — | — | — | — | — |
Balaji Venkataramanan Prasad | Chief Strategy Officer | — | — | — | — | — |
Joseph E. McClellan | Chief Operating Officer | — | — | 52 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +11.1% | +48.6% (7yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +11.1% over three years. Forward estimates point to Revenue at +48.6% (7yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Progyny, Inc.
NASDAQ:PGNY
$2.09B
Select Medical Holdings Corporation
NYSE:SEM
$2.07B
UFP Technologies, Inc.
NASDAQ:UFPT
$1.82B
Harrow Health, Inc.
NASDAQ:HROW
$1.40B
Phibro Animal Health Corporation
NASDAQ:PAHC
$1.28B
Biohaven Ltd.
NYSE:BHVN
$1.19B
Collegium Pharmaceutical, Inc.
NASDAQ:COLL
$1.12B
Evotec SE
NASDAQ:EVO
$966.11M
Amphastar Pharmaceuticals, Inc.
NASDAQ:AMPH
$885.83M
Tilray Brands, Inc.
NASDAQ:TLRY
$595.63M
Who manages ALVO?
Alvotech (ALVO) lists 14 active executives. The top listed executive is Benedikt Stefansson, Vice President of Investor Relations and Global Communications.
Explore More
Continue the stock analysis
Jump to another research area for this company.